Join AlphaMaven

The Home Of Private Equity

Register For Free Learn More Contact Us

Most Visited Alternative Investment Industry Website. Over 50,000 visitors per month

Private Equity Dashboard:

Click to subscribe to our Free Daily Newsletter

Top Private Equity News, Member Posts, Managed Futures Daily Indices and more!

Getting to grips with the growing CDMO opportunity – Adragos Pharma
2yrs ago Private Equity altassets Views: 507

Contract development and manufacturing organizations (CDMOs), suppliers to the pharma industry that develop and manufacture medicines, have become essential for today’s healthcare systems. About 25% of worldwide drug manufacturing is currently in the hands of these players, keeping medicines affordable and available. AltAssets spoke to investment specialist Adragos Pharma's founders to shed some light on this little-known but much sought-after industry segment.

Getting to grips with the growing CDMO opportunity – Adragos Pharma first appeared on AltAssets Private Equity News.


Today's Private Equity Headlines:

Most popular| Most recent
FEATURED MEMBER POST
Andrea Alms Video:  Money In Motion 101 - Deep Dive - Immunotherapy Cancer Market
Private Equity BrookDell Partners #Video
Log In for More
Access Over 250K+ Industry Headlines, Posts and Updates
Not a member yet?

Join AlphaMaven

The Premier Alternative Investment
Research and Due Diligence Platform for Investors

Free Membership for Qualified Investors and Industry Participants
  • Easily Customize Content to Match Your Investment Preferences
  • Breaking News 24/7/365
  • Daily Newsletter & Indices
  • Alternative Investment Listings & LeaderBoards
  • Industry Research, Due Diligence, Videos, Webinars, Events, Press Releases, Market Commentary, Newsletters, Fact Sheets, Presentations, Investment Mandates, Video PitchBooks & More!
  • Company Directory
  • Contact Directory
  • Member Posts & Publications
  • Alpha University Video Series to Expand Investor Knowledge
  • AUM Accelerator Program (designed for investment managers)
  • Over 450K+ Industry Headlines, Posts and Updates
Sign Up Now
CREATE A FREE MEMBERSHIP
View Private Equity Listings
AlphaMaven Daily Indices
Apr MTD ROR
AlphaMaven Private Equity Index:
3.8%
- more -
SPONSORED BY
Be Seen - Advertise With Us
Click to Discuss
FEATURED MEMBER POSTS
Andrea Alms Video:  Money In Motion 101 - Deep Dive - Immunotherapy Cancer Market
- posted by: BrookDell Partners
Andrea Alms Video:  Money In Motion 98 - Radiation Therapy Market
- posted by: BrookDell Partners
Andrea Alms Video:  Money In Motion 99 - Immunology Market
- posted by: BrookDell Partners
Andrea Alms Video:  Money In Motion 102 - Deep Dive Immunotherapy Cancer Market Part 3
- posted by: BrookDell Partners
Andrea Alms Video:  Money In Motion 100 - Cancer Market Wrap-Up
- posted by: BrookDell Partners
ALL ALPHAMAVEN CONTENT IS FOR INFORMATIONAL PURPOSES ONLY. CONTENT POSTED BY MEMBERS DOES NOT NECESSARILY REFLECT THE OPINION OR BELIEFS OF ALPHAMAVEN AND HAS NOT ALWAYS BEEN INDEPENDENTLY VERIFIED BY ALPHAMAVEN. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. THIS IS NOT A SOLICITATION FOR INVESTMENT. THE MATERIAL PROVIDED HEREIN IS FOR INFORMATIONAL PURPOSES ONLY. IT DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY INTERESTS OF ANY FUND OR ANY OTHER SECURITIES. ANY SUCH OFFERINGS CAN BE MADE ONLY IN ACCORDANCE WITH THE TERMS AND CONDITIONS SET FORTH IN THE INVESTMENT'S PRIVATE PLACEMENT MEMORANDUM. PRIOR TO INVESTING, INVESTORS ARE STRONGLY URGED TO REVIEW CAREFULLY THE PRIVATE PLACEMENT MEMORANDUM (INCLUDING THE RISK FACTORS DESCRIBED THEREIN), THE LIMITED PARTNERSHIP AGREEMENT AND THE SUBSCRIPTION DOCUMENTS, TO ASK SUCH QUESTIONS OF THE INVESTMENT MANAGER AS THEY DEEM APPROPRIATE, AND TO DISCUSS ANY PROSPECTIVE INVESTMENT IN THE FUND WITH THEIR LEGAL AND TAX ADVISERS IN ORDER TO MAKE AN INDEPENDENT DETERMINATION OF THE SUITABILITY AND CONSEQUENCES OF AN INVESTMENT.